

Board of Directors:	Ognian Donev, PhD Vessela Stoeva Alexandar Tchaoushev Bissera Lazarova Ivan Badinski
Executive Director:	Ognian Donev, PhD
Procurators:	Simeon Donev
Finance Director:	Boris Borisov
Preparer:	Lyudmila Bondzhova
Head of Legal Department:	Alexandar Yotov
Address of Management:	Sofia 16, Iliensko Shosse Str.
Lawyers:	Ventsislav Stoev
Servicing Banks:	KBS Bank DSK Bank EAD Eurobank and FG Bulgaria AD ING Bank N.V. UniCredit AD Citibank N.A. Municipal Bank AD
Auditor:	Baker Tilly Klitou and Partners OOD

SOPHARMA GROUP
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
for the six-month period ending 30 June 2023

	Notes	1 January - 30 June 2023 BGN'000	1 January - 30 June 2022 BGN'000
Revenue from contracts with customers	3	916 892	802 919
Other operating income / (losses), net	4	5 667	5 420
Changes in inventories of finished goods and work in progress		15 441	3 182
Raw materials and consumables used	5	(50 832)	(48 113)
Hired services expense	6	(40 019)	(32 929)
Employee benefits expense	7	(83 005)	(73 052)
Depreciation and amortization expense	14,15	(27 224)	(25 653)
Carrying amount of goods sold		(671 422)	(585 362)
Other operating expenses	8	(1 763)	(2 591)
Profit from operations		63 735	43 821
Finance income	10	1 794	2 124
Finance costs	11	(5 325)	(3 690)
Finance income/(costs), net		(3 531)	(1 566)
Profit from associates and joint ventures, net	12	12 734	9 968
Gain/(Loss) on acquisition and disposal of and from subsidiaries		-	-
Profit from acquisition and disposal of subsidiaries		-	-
Profit before tax		72 938	52 223
Income tax expense		(6 990)	(5 953)
Net profit for the period		65 948	46 270
Other components of comprehensive income:			
<i>Items that will not be reclassified to profit or loss:</i>			
Subsequent revaluations of property, plant and equipment		33	-
Net change in the fair value of other long-term equity investments	13	520	(340)
Income tax related to components of other comprehensive income that will not be reclassified		(3)	-
		550	(340)
<i>Items that may be reclassified to profit or loss:</i>			
Exchange differences on translating foreign operations		(317)	157
Share of other comprehensive income of associates		2 039	(127)
		1 722	30
Other comprehensive income for the period, net of tax	13	2 272	(310)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		68 220	45 960
Net profit for the year attributable to:			
Equity holders of the parent		63 462	43 365
Non-controlling interests		2 486	2 905
Total comprehensive income for the year attributable to:			
Equity holders of the parent		65 734	43 047
Non-controlling interests		2 486	2 913
Basic net profit per share	BGN	0,52	0,36
Net earnings per diluted share	BGN	0,51	0,37

The notes on pages 5 to 141 are an integral part of the present consolidated financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Preparer:

SOPHARMA GROUP
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
for the six-month period ending 30 June 2023

	Notes	30 June 2023 BGN'000	31 December 2022 BGN'000
ASSETS			
Non-current assets			
Property, plant and equipment	14	370 185	376 407
Intangible assets	15	46 312	48 151
Goodwill	15	3 494	3 522
Investment properties	16	10 752	10 568
Investments in associated and joint ventures	17	176 239	162 844
Other long - term equity investments	18	6 342	4 778
Long-term receivables from related parties	19	72 179	67 471
Other long-term receivables	20	7 628	5 694
Deferred tax assets		2 105	2 052
		695 236	681 487
Current assets			
Inventories	21	315 928	278 583
Commercial receivables	22	266 708	224 442
Receivables from related parties	23	14 538	12 909
Other short-term receivables and assets	24	39 796	36 702
Cash and cash equivalents	25	16 989	19 855
		653 959	572 491
TOTAL ASSETS		1 349 195	1 253 978
EQUITY AND LIABILITIES			
Equity attributable to equity holders of the parent			
Share capital		134 798	134 798
Reserves		45 722	47 503
Other capital components (reserve for issued warrants)		12 480	12 488
Retained earnings	26	504 339	509 869
		697 339	704 658
Non-controlling interests		14 177	11 976
TOTAL EQUITY	26	711 516	716 634
LIABILITIES			
Non-current liabilities			
Long-term bank loans	27	23 451	27 759
Deferred tax liabilities		5 824	6 397
Long-term liabilities to related parties	28	24 802	24 494
Long-term payables to personnel	29	6 700	6 541
Lease liabilities	30	54 648	52 058
Government grants	31	5 936	6 155
Other non-current liabilities	32	6 594	6 594
		127 955	129 998
Current liabilities			
Short-term bank loans	33	197 837	158 355
Short-term part of long-term bank loans	27	8 391	9 758
Trade payables	34	166 977	175 567
Payables to related parties	35	54 513	4 904
Factoring agreement liabilities	36	1 724	1 875
Short-term part of leasing liabilities	30	13 337	12 874
Payables to personnel and social security	37	21 674	21 780
Tax payables	38	8 911	8 436
Other current liabilities	39	36 360	13 797
		509 724	407 346
TOTAL LIABILITIES		637 679	537 344
TOTAL EQUITY AND LIABILITIES		1 349 195	1 253 978

The notes on pages 5 to 142 are an integral part of the present consolidated financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Preparer:

Lyudmila Bondzhova

SOPHARMA GROUP
CONSOLIDATED STATEMENT OF CASH FLOWS
for the six-month period ending 30 June 2023

	Notes	<i>1 January - 30 June 2023</i>	<i>1 January - 30 June 2022</i>
		BGN'000	BGN'000
Cash flows from operating activities			
Revenue from contracts with customers		1 010 640	896 510
Payments to suppliers		(893 465)	(760 656)
Payments for wages and social security		(81 426)	(69 550)
Taxes paid (profit tax excluded)		(33 019)	(34 906)
Taxes refunded (profit tax excluded)		3 076	3 267
Income taxes paid		(5 868)	(4 134)
Interest and bank charges paid on working capital loans		(3 614)	(2 533)
Exchange rate differences, net		(572)	(240)
Other proceeds/(payments), net		(1 139)	(422)
Net cash flows used in operating activities		(5 387)	27 336
Cash flows from investing activities			
Purchases of property, plant and equipment		(15 001)	(7 672)
Proceeds from sales of property, plant and equipment		6 060	1 148
Purchases of intangible assets		(3 283)	(1 904)
Purchases of equity investments		(1 345)	(363)
Purchases of other long-term capital investments		(101)	(1 041)
Proceeds from the sale of other long-term capital investments		28	-
Proceeds from sales of equity investments		(538)	(3 174)
Proceeds from sale of shares and stakes in subsidiaries		(4 050)	(1 500)
Loans granted to related parties		-	684
Loan repayments by related parties		(4 696)	-
Loans granted to other companies		129	859
Interest received on loans granted		-	12
Interest received on granted loans		(22 797)	(12 951)
Proceeds from charges under guarantees		-	-
Net cash flows from / (used in) investment activities		(22 797)	(12 951)
Cash flows from financial activities			
Proceeds from short-term bank loans (including increases in overdrafts)		40 626	-
Repayment of short-term bank loans (including decreases in overdrafts)		(1 188)	(41 350)
Proceeds from long-term bank loans		-	4 106
Repayment of long-term bank loans		(5 714)	(5 091)
Proceeds under factoring agreement		700	18 850
Interest paid under factoring agreement		(51)	(33)
Interest and charges paid under investment purpose loans		(212)	(176)
Lease payments		(9 166)	(8 602)
Treasury shares		-	(1 918)
Dividends paid		(5)	(6)
Government grants		36	16
Proceeds / (payments), net, related to other capital components (warrants)		(8)	102
Net cash flows from financial activities		25 018	(34 102)
Net increase/(decrease) in cash and cash equivalents		(2 865)	(18 705)
Cash and cash equivalents at 1 January		19 851	37 717
Cash and cash equivalents at 30 June	25	16 986	19 012

The notes on pages 5 to 142 are an integral part of the present consolidated financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Preparer:

Lyudmila Bondzhova